A popular honey product has been voluntarily recalled by its manufacturer, Akkarco, after the U.S. Food and Drug Administration (FDA) notified the company that samples of the product contained an undeclared drug—commonly used to treat erectile dysfunction—according to a press release issued by Akkarco on Janaury 28, 2026, and the official FDA announcement, which was published on February 3, 2026.
What Product Has Been Recalled?
The recall covers Ashfiat Alharamain Energy Support honey, which is packaged in a glass bottle with a gold lid and an orange label.
According to Akkarco’s press release, the product carries the Unified Product Code (UPC) 1234561870003, an expiration date of October 2028, and a batch number ENGOT24.
All identifying details are displayed on the back of the bottle.
Both the FDA and Akkarco state that the product was distributed nationwide through Akkarco’s website and through third‑party marketplaces, including Amazon.
Details of the Recall
The recall was initiated by Akkarco after the FDA notified the manufacturer that samples of the honey product contained undeclared tadalafil, a drug that’s often used to treat male erectile dysfunction.
Although tadalafil is FDA-approved, it can only be used “under medical supervision” and cannot be marketed as a supplement. According to the FDA announcement, the product is considered “an unapproved new drug for which safety and efficacy have not been established.”
Products containing undeclared tadalafil can cause health issues ranging from cardiovascular complications and blood‑pressure changes to dizziness and headaches. It can also potentially pose a risk to individuals taking certain medications.
At the time of publishing, no issues or adverse health effects had been reported to the company or the FDA in connection with the recalled product.
Advice for Consumers With the Recalled Product
Consumers who have purchased Ashfiat Alharamain Energy Support honey should stop using it immediately and follow return or disposal instructions provided by the seller or distributor, according to both the company’s announcement and the FDA notice.
Akkarco said that if consumers have any questions, they can email United Legal Experts at office@unitedlegalexperts.com, Monday through Friday, 8 a.m. to 4 p.m. ET.
Akkarco acknowledged that it is “working closely with its partners and platforms to ensure that all affected products are removed from distribution and sale.”
The company also said it “is committed to maintaining the trust and confidence of its customers and is implementing enhanced compliance, quality assurance, and supplier verification measures to prevent similar occurrences,” and “will continue to implement stringent measures to prevent such incidents in the future.”
Read the full article here
